A Bill to make provision for a warning symbol to be prominently displayed on the packaging of pharmaceuticals which act on the brain and central nervous system so as to impair dangerously the consumer’s ability to carry out certainactivities; and for connected purposes.
The Bill would make provision for a warning symbol to be prominently displayed on the packaging of specified psychoactive pharmaceuticals, which act on the brain and central nervous system and which can impair dangerously the consumer’s ability to carry out certain activities.
House of Commons
9 November 2009
May contain errors — check source documents for definitive information.
The Pharmaceutical Labelling (Warning Of Cognitive Function Impairment) Bill would require a prominently displayed warning symbol on the packaging of certain medicines that act on the brain and central nervous system and can dangerously impair a person’s ability to carry out tasks. The aim is to help people recognise when a drug may affect thinking or reaction and to reduce harm; it applies to specified psychoactive medicines and related purposes.
The bill is at the 2nd reading in the House of Commons. Its earlier stage was the 1st reading in 2009; no further stages are listed in the provided data.
Generated 21 February 2026
26 Jan 2009
This Bill was presented to Parliament on 26 January. This is known as First Reading and there was no debate on the Bill at this stage.
The Bill was on the Order Paper for a Second Reading on several Fridays before being dropped by its sponsor, Mr Andrew Dismore.
No recorded votes for this bill yet.
